Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript BiotechGNNSF +17.28%72 Earnings per Share (Diluted) is $-0.29 as of Jun. 2026. GuruFocus rates GNNSF with a GF Score™ of 72/100 and a GF Value™ of $2.41 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,155 Biotechnology companies, Genscript Biotech ranks worse than 69.61% on this metric.
Genscript Biotech's EPS (Basic) for the
six
months ended in Jun. 2026 was $-0.06.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.29.
During the past 3 years, the average EPS without NRIGrowth Rate was 0.90% per year.
During the past 13 years, Genscript Biotech's highest 3-Year average EPS without NRI Growth Rate was 56.50% per year. The lowest was -25.30% per year. And the median was 8.30% per year.
Genscript Biotech (OTCPK:GNNSF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Genscript Biotech Earnings per Share (Diluted) Related Terms
Genscript Biotech Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech Earnings per Share (Diluted) Chart
GNNSF vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Genscript Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's PE Ratio distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's PE Ratio falls into.
Genscript Biotech Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Genscript Biotech's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.29 mean?
Genscript Biotech (GNNSF) has a Earnings per Share (Diluted) of $-0.29 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #804 out of 1155 companies in the Biotechnology industry, placing it in the top 69.6%.
Is Genscript Biotech's Earnings per Share (Diluted) too high?
Genscript Biotech's current Earnings per Share (Diluted) is $-0.29. Based on the distribution chart, Genscript Biotech ranks #804 out of 1155 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #804 out of 1155 companies for Earnings per Share (Diluted). This places Genscript Biotech in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Earnings per Share (Diluted) is $-0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $5.65 — trading 134.4% above its estimated fair value. The current Earnings per Share (Diluted) is $-0.29. Genscript Biotech's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Earnings per Share (Diluted) is $-0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued.
The current stock price of $5.65 is trading 134.4% above its estimated GF Value™ of $2.41.
GuruFocus considers Genscript Biotech to be Significantly Overvalued.
Key valuation signals for GNNSF:
Earnings per Share (Diluted): $-0.29
GF Value™: $2.41 vs. price of $5.65 (134.4% above fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
72GF Score
Get the complete analysis for GNNSF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
